Gabulova R, Marzà-Florensa A, Rahimov U, Isayeva M, Alasgarli S, Musayeva A, Gahramanova S, Ibrahimov F, Aliyev F, Imanov G, Rasulova R, Vaartjes I, Klipstein-Grobusch K, Graham I, Grobbee DE. Risk factors in cardiovascular patients: Challenges and opportunities to improve secondary prevention. World J Cardiol 2023; 15(7): 342-353 [PMID: 37576543 DOI: 10.4330/wjc.v15.i7.342]
Corresponding Author of This Article
Rahima Gabulova, MD, PhD, FESC, Associate Professor, Teaching-Therapeutical Hospital, Azerbaijan Medical University, 100 Mardanov Brothers, Baku AZ1022, Azerbaijan. rahima.gabulova@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jul 26, 2023; 15(7): 342-353 Published online Jul 26, 2023. doi: 10.4330/wjc.v15.i7.342
Table 1 Demographic characteristics and disease category of the patients (n = 687)
Total, n = 687
Female, n = 171
Male, n = 516
P value
Age (years)
59.6 ± 9.58
62.4 ± 8.9
58.6 ± 9.6
< 0.0001
CHD category, n (%)
CABG
153 (22.3)
41 (24)
112 (22)
> 0.05
PCI
351 (51.1)
71 (42)
280 (54)
0.004
ACS
172 (25.0)
27 (16)
145 (28)
0.001
SAP
249 (36.2)
82 (48)
167 (32)
0.0002
HA
271 (39.4)
68 (40)
203 (39)
> 0.05
CR
104 (15.1)
19 (11.1)
85 (16.5)
> 0.05
Table 2 Cardiovascular risk factors stratified by sex, n (%)
Total, n = 687
Female, n = 171
Male, n = 516
P value
Smoking history
Current smoker
169 (24.6)
3 (1.8)
166 (32)
< 0.00001
Ex-smoker
169 (24.6)
2 (1.2)
167 (32)
< 0.00001
Never smoked
314 (45.7)
165 (96.5)
149 (29)
< 0.00001
Unknown
35 (5.1)
1 (0.6)
34 (7)
Physical activity
Less than below
223 (32.5)
66 (38.6)
157 (30.4)
> 0.05
Moderate
324 (47.2)
74 (43.3)
250 (48.4)
> 0.05
More than above
82 (11.9)
19 (11.1)
63 (12.2)
> 0.05
Unknown
58 (8.4)
12 (7.02)
46 (8.9)
Family history of premature CVD
Yes
265 (38.6)
58 (33.9)
207 (40.1)
> 0.05
No
355 (51.7)
96 (56.1)
259 (50.2)
> 0.05
Unknown
67 (9.8)
17 (9.9)
50 (9.7)
Previous history of
Hypertension
537 (78.2)
142 (83)
395 (76.6)
> 0.05
Dyslipidaemia
255 (37.1)
60 (35.1)
195 (37.8)
> 0.05
Diabetes
310 (45.1)
95 (55.6)
215 (41.7)
0.002
Table 3 Clinical measurements and laboratory data of the patients (mean ± SD)
Total
Female
Male
P value
Systolic BP (mmHg)
n = 663
n = 164
n = 499
138.4 (18.9)
142.4 (1.4)
137.1 (17.9)
0.004
Diastolic BP (mmHg)
n = 658
n = 162
n = 496
82.9 (10.7)
82.7 (11.5)
82.8 (10.4)
> 0.05
Heart rate (bmp)
n = 649
n = 156
n = 493
77.6 (12.7)
78.5 (12.0)
77.3 (12.9)
> 0.05
BMI (kg/m2)
n = 216
n = 50
n = 166
28.4 (3.02)
29.6 (3.4)
28 (2.8)
0.002
WC (cm)
n = 30
n = 13
n = 17
101 (12.9)
100.8 (15.2)
101.0 (11.3)
> 0.05
TC (mg/dL)
n = 347
n = 86
n = 261
193.9 (52.4)
200.4 (50.7)
192.3 (53)
> 0.05
LDL-C (mg/dL)
n = 371
n = 101
n = 270
111.2 (49.6)
118.3 (49.7)
108.6 (49.3)
> 0.05
HDL-C (mg/dL)
n = 185
n = 50
n = 135
53.4 (13.8)
54.4 (13.1)
53 (14.1)
> 0.05
TG (mg/dL)
n = 367
n = 93
n = 274
161.0 (76.0)
169.8 (77.8)
158 (75.4)
> 0.05
BG (mg/dL)
n = 277
n = 73
n = 204
146.7 (71.5)
162.7 (79.9)
141 (67.5)
0.04
HbA1c (%)
n = 137
n = 44
n = 93
7.71 (1.72)
8.1 (2.0)
7.5 (1.5)
> 0.05
Table 4 Rates of uncontrolled blood pressure in different categories of arterial hypertension
BP category, n = 658
Total (%)
Female (%)
Male (%)
P value
SDH
27.5
27.8
27.4
0.929
ISH
20.9
26.8
18.8
0.029
IDH
6.8
6.8
6.9
0.977
Table 5 Medication use rate in patients with known coronary artery disease (%)
Medications
Total
Male
Female
P value
n = 687
n = 516
n = 171
Antiplatelets
84.6
85.3
82.5
0.377
Beta blockers
53.3
55.2
47.4
0.074
ACE inhibitors
51.2
49.0
57.9
0.044
Ca antagonists
29.3
28.7
31.0
0.565
ARB-s
6.0
5.8
6.4
0.767
Diuretics
22.3
20.5
27.5
0.059
Other antihypertensives
2.3
1.9
3.5
0.238
Nitrates
21.3
7.6
62.6
< 0.00001
Insulin
7.6
6.4
11.1
0.043
Oral hypoglycaemics
23
20.9
29.2
0.025
Statins
73.9
76.4
66.7
0.012
Other lipid lowering
1.3
1.2
1.8
0.555
Citation: Gabulova R, Marzà-Florensa A, Rahimov U, Isayeva M, Alasgarli S, Musayeva A, Gahramanova S, Ibrahimov F, Aliyev F, Imanov G, Rasulova R, Vaartjes I, Klipstein-Grobusch K, Graham I, Grobbee DE. Risk factors in cardiovascular patients: Challenges and opportunities to improve secondary prevention. World J Cardiol 2023; 15(7): 342-353